prednisone has been researched along with Bone Diseases, Metabolic in 29 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare bone mass loss due to deflazacort versus prednisone in longterm treatment of patients with giant cell arteritis (GCA) in a randomized double blind comparative trial." | 9.09 | Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. ( Belmatoug, N; Cacoub, P; Chemlal, K; Cohen, P; De Gennes, C; Khalifa, P; Piette, JC; Verdoncq, B; Wechsler, B; Ziza, JM, 2001) |
| "To compare bone mass loss due to deflazacort versus prednisone in longterm treatment of patients with giant cell arteritis (GCA) in a randomized double blind comparative trial." | 5.09 | Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. ( Belmatoug, N; Cacoub, P; Chemlal, K; Cohen, P; De Gennes, C; Khalifa, P; Piette, JC; Verdoncq, B; Wechsler, B; Ziza, JM, 2001) |
| "In this retrospective, cross-sectional case series, 18 patients with patchy alopecia areata treated at 4- to 8-week intervals with intralesional triamcinolone acetonide for at least 20 months were evaluated for BMD using dual-energy x-ray absorptiometry (DXA)." | 3.79 | Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. ( Fu, JM; Harris, ST; Price, VH; Samrao, A, 2013) |
| " It is suggested that cyclosporine, together with the decrease of prednisone dosage but independent of renal function, PTH, and vitamin D status, contributes to a transient stimulation of bone remodeling at six months, which counterbalances the deleterious effect of prednisone on bone formation and BMD." | 2.69 | Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. ( Achard, JM; Brazier, M; El Esper, I; Ezaitouni, F; Fardellone, P; Fournier, A; Hottelart, C; Ivan, C; Mazouz, H; Petit, J; Pruna, A; Westeel, FP, 2000) |
| " It is clear that new dosing arrangements need to be created and studied." | 2.39 | Corticosteroids in the treatment of rheumatologic diseases. ( Weisman, MH, 1995) |
| "Osteopenia was a consistent preexisting radiographic feature." | 2.38 | Rapidly progressive protrusio acetabuli in patients with rheumatoid arthritis. ( Damron, TA; Heiner, JP, 1993) |
| "Osteoporosis is a common concomitant disease in patients with rheumatic diseases on glucocorticoid (GC) therapy." | 1.33 | Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. ( Bohl, N; Burmester, GR; Buttgereit, F; Loddenkemper, K; Perka, C, 2006) |
| "Osteoporosis is defined as a bone mineral density (BMD) value evaluated by dual-energy X-linked absorptiometry of the lumbar spine of a z score of 2." | 1.32 | Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? ( Godbole, M; Gulati, K; Gulati, S; Singh, U; Srivastava, A, 2003) |
| "Low bone density is frequent in both CD and UC, but apparently stable in CD." | 1.30 | Evolution of osteopenia in inflammatory bowel disease. ( Bottega, F; Dinca, M; Fries, W; Leone, L; Luisetto, G; Martin, A; Naccarato, R; Peccolo, F, 1999) |
| "Osteopenia has been observed to occur frequently after renal transplantation." | 1.29 | Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. ( Bognar, B; Briner, VA; Kamber, V; Landmann, J; Malluche, HH; Monier-Faugere, MC; Thiel, G, 1995) |
| "Other 16 patients with low bone mineral density have received also calcitonin (100 units subcutaneous daily) with vitamin D3 and calcium carbonate." | 1.29 | [Effect of calcitonin treatment on bone mineralization in patients with multiple myeloma]. ( Kuratowska, Z; Niesiobedzka-Krezel, J; Ostrowski, G; Ostrowski, K; Paluszewska, M; Paprocka, E; Przedlacki, J; Swieboda, A; Walter, Z, 1995) |
| " Vertebral fractures (VF) were found in four men and were associated with higher prednisone dosage (P < 0." | 1.29 | Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. ( Bonnardeaux, A; Cardinal, J; Gagné, M; Ouimet, D; Pichette, V; Prudhomme, L, 1996) |
| "Prednisone treatment resulted in diminished bone formation rates (15 +/- 3." | 1.28 | Prednisone-induced osteopenia in beagles: variable effects mediated by differential suppression of bone formation. ( Quarles, LD, 1992) |
| "Osteopenia is a major complication of renal transplantation." | 1.28 | Rapid loss of vertebral mineral density after renal transplantation. ( Curtis, JJ; Dubovsky, EV; Dubovsky, J; Julian, BA; Laskow, DA; Quarles, LD, 1991) |
| "Deflazacort was substituted for Prednisone (based on the equivalence 1 mg Prednisone equals 1." | 1.27 | Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth. ( Balsan, S; Bourdeau, A; Grimberg, R; Lenoir, G; Stéru, D, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.34) | 18.7374 |
| 1990's | 13 (44.83) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fumoto, T | 1 |
| Ishii, KA | 1 |
| Ito, M | 1 |
| Berger, S | 1 |
| Schütz, G | 1 |
| Ikeda, K | 1 |
| Zoulek, ES | 1 |
| Karp, DR | 1 |
| Davila, GW | 1 |
| Samrao, A | 1 |
| Fu, JM | 1 |
| Harris, ST | 1 |
| Price, VH | 1 |
| Devogelaer, JP | 1 |
| Gennari, C | 1 |
| Gulati, S | 2 |
| Godbole, M | 1 |
| Singh, U | 2 |
| Gulati, K | 2 |
| Srivastava, A | 2 |
| de Deus, RB | 1 |
| Ferreira, AC | 1 |
| Kirsztajn, GM | 1 |
| Heilberg, IP | 1 |
| RICH, C | 1 |
| ENSINCK, J | 1 |
| IVANOVICH, P | 1 |
| Loddenkemper, K | 1 |
| Bohl, N | 1 |
| Perka, C | 1 |
| Burmester, GR | 1 |
| Buttgereit, F | 1 |
| Sharma, RK | 1 |
| Grote, FK | 1 |
| Van Suijlekom-Smit, LW | 1 |
| Mul, D | 1 |
| Hop, WC | 1 |
| Ten Cate, R | 1 |
| Oostdijk, W | 1 |
| Van Luijk, W | 1 |
| Jansen-van Wijngaarden, CJ | 1 |
| De Muinck Keizer-Schrama, SM | 1 |
| Almoznino-Sarafian, D | 1 |
| Dotan, E | 1 |
| Sandbank, J | 1 |
| Gorelik, O | 1 |
| Chachashvily, S | 1 |
| Shteinshnaider, M | 1 |
| Cohen, N | 1 |
| Weisman, MH | 1 |
| Briner, VA | 1 |
| Thiel, G | 1 |
| Monier-Faugere, MC | 1 |
| Bognar, B | 1 |
| Landmann, J | 1 |
| Kamber, V | 1 |
| Malluche, HH | 1 |
| Damron, TA | 1 |
| Heiner, JP | 1 |
| Przedlacki, J | 1 |
| Paluszewska, M | 1 |
| Ostrowski, G | 1 |
| Paprocka, E | 1 |
| Swieboda, A | 1 |
| Niesiobedzka-Krezel, J | 1 |
| Walter, Z | 1 |
| Ostrowski, K | 1 |
| Kuratowska, Z | 1 |
| Guaydier-Souquières, G | 1 |
| Kotzki, PO | 1 |
| Sabatier, JP | 1 |
| Basse-Cathalinat, B | 1 |
| Loeb, G | 1 |
| Pichette, V | 1 |
| Bonnardeaux, A | 1 |
| Prudhomme, L | 1 |
| Gagné, M | 1 |
| Cardinal, J | 1 |
| Ouimet, D | 1 |
| Garcia-Delgado, I | 1 |
| Prieto, S | 1 |
| Gil-Fraguas, L | 1 |
| Robles, E | 1 |
| Rufilanchas, JJ | 1 |
| Hawkins, F | 1 |
| Dinca, M | 1 |
| Fries, W | 1 |
| Luisetto, G | 1 |
| Peccolo, F | 1 |
| Bottega, F | 1 |
| Leone, L | 1 |
| Naccarato, R | 1 |
| Martin, A | 1 |
| Westeel, FP | 1 |
| Mazouz, H | 1 |
| Ezaitouni, F | 1 |
| Hottelart, C | 1 |
| Ivan, C | 1 |
| Fardellone, P | 1 |
| Brazier, M | 1 |
| El Esper, I | 1 |
| Petit, J | 1 |
| Achard, JM | 1 |
| Pruna, A | 1 |
| Fournier, A | 1 |
| Cayco, AV | 1 |
| Wysolmerski, J | 1 |
| Simpson, C | 1 |
| Mitnick, MA | 1 |
| Gundberg, C | 1 |
| Kliger, A | 1 |
| Lorber, M | 1 |
| Silver, D | 1 |
| Basadonna, G | 1 |
| Friedman, A | 1 |
| Insogna, K | 1 |
| Cruz, D | 1 |
| Bia, M | 1 |
| Cacoub, P | 1 |
| Chemlal, K | 1 |
| Khalifa, P | 1 |
| Wechsler, B | 1 |
| De Gennes, C | 1 |
| Belmatoug, N | 1 |
| Cohen, P | 1 |
| Ziza, JM | 1 |
| Verdoncq, B | 1 |
| Piette, JC | 1 |
| Splain, J | 1 |
| Berman, BW | 1 |
| Quarles, LD | 2 |
| Julian, BA | 1 |
| Laskow, DA | 1 |
| Dubovsky, J | 1 |
| Dubovsky, EV | 1 |
| Curtis, JJ | 1 |
| Luengo, M | 1 |
| Picado, C | 1 |
| Del Rio, L | 1 |
| Guañabens, N | 1 |
| Montserrat, JM | 1 |
| Setoain, J | 1 |
| LoCascio, V | 1 |
| Bonucci, E | 1 |
| Imbimbo, B | 1 |
| Ballanti, P | 1 |
| Adami, S | 1 |
| Milani, S | 1 |
| Tartarotti, D | 1 |
| DellaRocca, C | 1 |
| Schattner, A | 1 |
| Varon, D | 1 |
| Green, L | 1 |
| Hurwitz, N | 1 |
| Bentwich, Z | 1 |
| Balsan, S | 1 |
| Stéru, D | 1 |
| Bourdeau, A | 1 |
| Grimberg, R | 1 |
| Lenoir, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata[NCT04793945] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackf[NCT01362595] | Phase 1/Phase 2 | 55 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary outcome is the type of response observed at 9 months. Response to treatment can be one of the following:~Complete response (CR): Hb > 9 gm/dL and transfusion-independence as defined in DBA~Partial response (PR): Hb < 9 gm/dL and increased reticulocyte count to greater than baseline.~No response (NR): no change in transfusion requirements and no significant change reticulocyte count from baseline~Progression: worsening of disease as defined by the need for more frequent transfusions" (NCT01362595)
Timeframe: 9 Months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Hematologic Response | Partial hematologic response | No hematologic response | Progression | |
| Leucine | 2 | 5 | 36 | 0 |
2 reviews available for prednisone and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Corticosteroids in the treatment of rheumatologic diseases.
Topics: Adrenal Cortex Hormones; Bone Diseases, Metabolic; Drug Administration Schedule; Gout; Humans; Hypot | 1995 |
Rapidly progressive protrusio acetabuli in patients with rheumatoid arthritis.
Topics: Acetabulum; Adult; Aged; Anthropometry; Arthritis, Rheumatoid; Bone Diseases, Metabolic; Diagnosis, | 1993 |
6 trials available for prednisone and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia.
Topics: Adolescent; Anthropometry; Body Composition; Bone Density; Bone Diseases, Metabolic; Child; Child, P | 2006 |
In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Adult; Aged; Bone Density; Bone Diseases, | 1996 |
Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation.
Topics: Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Calcifediol; Calcitonin; Calcium; Crea | 1997 |
Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Topics: Absorptiometry, Photon; Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Bon | 2000 |
Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bone Density; Bone | 2001 |
Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study.
Topics: Asthma; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Calcium; Female; Follow | 1990 |
21 other studies available for prednisone and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Eplerenone; Glucocorticoids; Mice; Mice, Inbred S | 2014 |
Did drug therapy contribute?: severe pelvic organ prolapse followed initiation of high-dose glucocorticoid treatment.
Topics: Aged; Bone Diseases, Metabolic; Diabetes Mellitus; Estrogens; Female; Glucocorticoids; Gynecologic S | 2012 |
Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Alopecia Areata; Anti-Inf | 2013 |
Deflazacort in giant cell arteritis.
Topics: Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Calcifediol; Dietary Supplements; | 2002 |
Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Calcium, D | 2003 |
Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Ca | 2003 |
THE EFFECTS OF SODIUM FLORIDE ON CALCIUM METABOLISM OF SUBJECTS WITH METABOLIC BONE DISEASES.
Topics: Blood; Body Fluids; Bone Diseases, Metabolic; Calcium; Diet; Feces; Fluorides; Geriatrics; Metabolis | 1964 |
Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Di | 2006 |
Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements.
Topics: Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Calcium; Child; Child, Preschool; | 2005 |
Unusual manifestations of myelofibrosis in a patient with congenital asplenia.
Topics: Adult; Anti-Bacterial Agents; Bone Diseases, Metabolic; Disease Susceptibility; Erythema Nodosum; Fe | 2007 |
Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Density; Bone Diseases, | 1995 |
[Effect of calcitonin treatment on bone mineralization in patients with multiple myeloma].
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Calcification, Physiologic; Calcitonin; Calcium Carbon | 1995 |
Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study.
Topics: Adult; Bone Density; Bone Diseases, Metabolic; Cross-Sectional Studies; Female; Follow-Up Studies; G | 1996 |
Evolution of osteopenia in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Body Mass Index; Bone Density; Bone Diseases, Metab | 1999 |
Posttransplant bone disease: evidence for a high bone resorption state.
Topics: Adult; Aged; Amino Acids; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cross-Se | 2000 |
Cyclosporin A treatment for Diamond-Blackfan anemia.
Topics: Adolescent; Bone Diseases; Bone Diseases, Metabolic; Child; Child, Preschool; Cyclosporine; Drug Adm | 1992 |
Prednisone-induced osteopenia in beagles: variable effects mediated by differential suppression of bone formation.
Topics: Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Dogs; Male; Osteogenesis; Prednison | 1992 |
Rapid loss of vertebral mineral density after renal transplantation.
Topics: Adult; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Calcitriol; Female; Humans; Ili | 1991 |
Bone loss in response to long-term glucocorticoid therapy.
Topics: Adult; Aged; Bone Diseases, Metabolic; Drug Therapy, Combination; Female; Humans; Longitudinal Studi | 1990 |
Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
Topics: Amyloidosis; Bone Diseases, Metabolic; Bone Marrow; Colchicine; Drug Therapy, Combination; Female; H | 1989 |
Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Body Height; Bone and Bones; Bone Di | 1987 |